Form 4: Ginkgo Bioworks Director Arie Belldegrun Reports Stock Transactions

Director Arie Belldegrun reports acquisition and disposal of Class A Common Stock and derivative securities in Ginkgo Bioworks Holdings, Inc.

Summary

• A Form 4 filing reveals changes in beneficial ownership for Arie Belldegrun, a director of Ginkgo Bioworks Holdings, Inc.
• On June 12, 2024, Belldegrun acquired 105,263 shares of Class A Common Stock and disposed of 105,263 shares related to vested Restricted Stock Units (RSUs).
• Following these transactions, Belldegrun directly owns 194,925 shares of Class A Common Stock and indirectly owns 500,000 shares through Bellco Legacy LLC.
• On June 13, 2024, Belldegrun acquired 432,900 Restricted Stock Units and 571,428 stock options with an exercise price of $0.462.
• The vesting date for the RSUs and the date the stock options become exercisable is the earlier of June 13, 2025, or the day before the next Annual Meeting of Shareholders, contingent on continued service as a Non-Employee Director.
• The Black-Scholes value of the option award as of the grant date is $200,000.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document primarily reports transactions. The acquisition of options and RSUs could be interpreted as mildly positive, indicating confidence in the company's future.

Positives

• The acquisition of stock options and RSUs could be seen as a positive sign, indicating the director's belief in the company's future performance.

Future Outlook

The vesting and exercisability of the RSUs and stock options are contingent on the director's continued service, suggesting a commitment to the company's future.

Industry Context

Form 4 filings are standard disclosures for company insiders and provide transparency into their transactions, allowing investors to track insider sentiment and potential alignment with company performance.

Stakeholder Impact

• Shareholders can use this information to assess insider sentiment and potential alignment with company goals.

Key Dates